Innovating Works

PHARMAHUNG

Desconocido
EVEREST: Extracellular Vesicle Research Exchanges for Advanced Biomarkers and Therapeutics The EVEREST project is a pioneering consortium in Extracellular Vesicle (EVs) research, bringing together 22 institutions from 11 countries,...
2024-08-01 - 2028-12-31 | Financiado
COVIRNA: A diagnostic test to improve surveillance and care of COVID 19 patients PHARMAHUNGARY 2000 KISERLETES ES KLINIKAI KUTATASFEJLESZTESI KORLATOLTFELELOSSEGU TARSASAG participó en un H2020: H2020-SC1-PHE-CORONAVIRUS-2020-2 Coronavirus disease 2019 (COVID-19) caused by infection with SARS coronavirus 2 (SARS-CoV-2) has reached pandemic proportions with more than...
2020-10-13 - 2023-04-30 | Financiado
CRYSTAL3: Commercial Research Opportunity for Cysteinyl Leukotriene Signalling in Ocular CNS Dysfunction... PHARMAHUNGARY 2000 KISERLETES ES KLINIKAI KUTATASFEJLESZTESI KORLATOLTFELELOSSEGU TARSASAG participó en un H2020: H2020-MSCA-RISE-2020 Cysteinyl leukotrienes (CysLTs) are potent lipid mediators of inflammation. CysLT1 and 2 receptors are widely expressed e.g. lungs, colorect...
2020-10-02 - 2024-12-31 | Financiado
Infarnosys: Novel biomarker diagnostic system for the assessment of the prognosis of acute myocardial ischemia r... PHARMAHUNGARY 2000 KISERLETES ES KLINIKAI KUTATASFEJLESZTESI KORLATOLTFELELOSSEGU TARSASAG tramitó un H2020: H2020-SMEInst-2014-2015 The Infarnosys project aims to launch a novel, combined biomarker diagnostic system on the market that will help clinicians and laboratories...
2015-09-07 - 2016-02-29 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.